Rational polypharmacy  by Richens, Alan
Seizure 1995; 4:211-214 
Rational polypharmacy 
ALAN RICHENS 
Professor of Pharmacology and Therapeutics, Department of Pharmacology and Therapeutics, University of 
Wales College of Medicine, Cardiff, UK 
The development of assays for plasma antiepileptic drug concentrations has led to the discovery of many 
pharmacokinetic interactions, ome causing drug intoxication and others resulting in ineffective drug concen- 
trations. In the 1970s, a number of epileptologists began to argue that single drug therapy was desirable in the 
treatment of epilepsy and this has become the accepted policy when initiating therapy. About 75% of patients 
treated in this way will achieve remission with a minimum of adverse drug reactions. The remainder, however, 
continue to have unacceptable s izures and usually receive combinations ofdrugs. Evidence indicates that the 
response rate on adding a second rug is low, although in some studies of new drugs such asvigabatrin up to 
one-half of patients receiving add-on therapy experience a 50% or greater eduction in seizure frequency, and 
10-15% are seizure-free in the short term. Unfortunately, randomized placebo-controlled studies have not 
been undertaken to compare the relative merits of monotherapy and combination therapy with respect of 
seizure control and adverse ffects. It is argued that the time has come to do so, particularly in view of the 
known mode of action of some of the new drugs. Perhaps blocking excitation with one drug at the same time as 
enhancing inhibition with another may be better than doing only one or the other. 
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INTRODUCTION 
It used to be thought that low doses of two 
drugs in combination gave a greater thera- 
peutic effect with less risk of toxicity than a 
larger dose of a single drug for the treatment of 
epilepsy. Now, however, the argument has 
swung the other way towards monotherapy, 
and it is felt that a full dose of one drug 
achieves better control of seizures with fewer 
adverse effects. The truth probably lies some- 
where in between: one drug is adequate for the 
majority of patients, but a small proportion 
may require the benefits of rational combi- 
nation therapy. This paper reviews the evi- 
dence which has led to current thinking and 
considers the debate between monotherapy 
and combination therapy. It also highlights the 
need for more scientific evaluation into the 
effects of combining antiepileptic drugs, so that 
combination therapy in epilepsy becomes a 
rational and logical exercise, instead of a 
random one, as is largely the case at present. 
THE BASIS OF THE MONOTHERAPY 
ARGUMENT 
The prevailing opinion among epileptologists 
nowadays is that single drug therapy for all 
patients is the desirable goal in the treatment 
of epilepsy. This view can be traced to several 
influential studies published in the late 1970s 
and early 1980s which evaluated the effects of 
adding a second drug to a patient's seizure- 
control regimen. A retrospective study of 50 
patients by Shorvon and Reynolds in 19771 
found that the addition of a second drug im- 
proved seizure control in only 18 patients 
(36%). It was concluded by the authors of this 
study that polypharmacy may, in many cases, 
be unnecessary. In 1979 the same authors 
carried out an open, prospective study of 40 
patients (without a control group), to examine 
the effects of reducing combination therapy to 
monotherapy 2. They concluded that mono- 
therapy was not possible in 11 patients (27%). 
Of the 29 patients who were reduced to mono- 
therapy treatment, 16 were judged to have be- 
come improved, eight remained unchanged 
and five patients were judged to have become 
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worse clinically. This provided further evi- 
dence that only a proportion of patients eemed 
to benefit from a combination of antiepileptic 
drugs. 
In 1981 Reynolds and Shorvon 3 identified 
four problems associated with polytherapy: (1) 
the possibility of long-term toxicity from the 
drug combination, (2) drug interactions, (3) the 
failure to evaluate individual drugs in individ- 
ual patients if one moves too swiftly towards 
combination therapy, and finally (4) the 
exacerbation of seizures, which the authors 
witnessed in some of their patients and which 
has been reported by many others. In 1982 
Schmidt 4 contributed to the growing evidence 
against polytherapy with a study of 30 patients 
who had complex partial seizures. A second 
drug was added to the existing treatment regi- 
men and found that a reduction in seizure fre- 
quency of >75% was seen in only 13% of 
patients. In three patients the seizure fre- 
quency was increased by >100%. This may 
have been either a response to the addition of 
the second drug or a random occurrence, as 
seizure frequency does fluctuate. The same 
author then carried out a study similar to that 
performed by Reynolds and Shorvon 5, in a 
prospective trial of 36 patients. Seizure control 
improved in 13 patients (36%), remained 
unchanged in 17 patients (47%) and deterio- 
rated in six patients (17%). The results of these 
studies led to the feeling among epileptologists 
that monotherapy was the way to treat epi- 
lepsy. 
THE DEBATE: MONOTHERAPY VS RATIONAL 
COMBINATION THERAPY 
The case for monotherapy has never been 
proven by a controlled, randomized trial. 
Neither has the case for combination therapy. 
No study has been carried out to compare the 
effects of two drugs in combination vs .  one drug 
alone. 
The question, therefore, is whether mono- 
therapy or rational combination therapy, i.e. 
targeting drugs in a logical way to achieve an 
optimum effect rather than mixing them up in 
a random fashion, should be used as standard 
treatment. Rational combination therapy is 
not new. It is the norm in many other areas of 
therapeutics uch as Parkinsonism, hyper- 
tension, asthma and antibiotic therapy. It is 
common even in epilepsy therapy. Many prac- 
titioners know that while they may aim for 
monotherapy, around 50% of their patients 
will be on two drugs or more. Furthermore, 
many old drugs have multiple sites of action, 
and are in fact 'combination therapy' in one 
drug. 
The three new drugs currently on the 
market--vigabatrin, gabapentin and lamotri- 
gine--have all been assessed in classical 'add- 
on' trials, and have therefore all been licensed 
for 'add-on' therapy. Until monotherapy trials 
are performed on these drugs we cannot recom- 
mend their use for monotherapy. These trials 
are now under way, but results will not be 
available for a few more years. 
DRUG ACTION AS A BASIS FOR RATIONAL 
COMBINATION THERAPY 
To be able to develop a rational system for com- 
bining drugs it is important o know as much 
as possible about the efficacy of each drug in 
different seizure types. The mechanisms of 
action of antiepileptic drugs do not generally 
give much guidance as to their therapeutic effi- 
cacy. The only correlation between pharmaco- 
logical action of drugs as studied in animals 
and clinical efficacy in patients is that drugs 
which act on fast sodium channels appear to be 
effective in tonic-clonic and partial seizures. 
Ethosuximide has a specific effect on calcium 
channels and is useful in absence seizures. But 
the correlation breaks down in the case of val- 
proate, which is also useful in absence seizures 
and does not work through calcium channels. 
It is therefore difficult to extrapolate from 
experimental data. Data from clinical evidence 
in published reports are more reliable. Our ex- 
perience has been that sodium valproate has a 
wide spectrum of activity, while drugs like car- 
bamazepine and phenytoin are more limited in 
the range of their action, particularly in myo- 
clonus and absence seizures. Valproate, due to 
its broad spectrum, is therefore my drug of 
choice for a wide range of seizures, particularly 
for practitioners who are less familiar with the 
treatment of epilepsy. 
WHERE DO THE NEW DRUGS FIT IN? 
Targeting the tried and tested drugs accu- 
rately still poses a challenge, and therefore it is 
an even more difficult task when we consider 
the newer agents. Data published so far 
suggest hat lamotrigine has a broad spectrum 
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of activity, although it is less useful in myo- 
clonus. 
There is growing evidence for the efficacy of 
felbamate, not only in refractory partial seiz- 
ures but also in Lennox-Gastaut syndrome 
and primary generalized seizures, so the indi- 
cations for felbamate may extend in the future. 
THE NEED FOR GREATER EVALUATION OF 
EFFECTIVE COMBINATIONS 
The creed for monotherapy has held back objec- 
tive evaluation of drug combinations and the 
time has come for a reappraisal of the situ- 
ation. A combination of drugs may have a 
beneficial effect through pharmacokinetic or 
pharmacodynamic interaction. A good example 
of the former is the combination of valproate 
and lamotrigine, where valproate inhibits 
lamotrigine metabolism. Less is understood 
about pharmacodynamic interactions, in which 
drugs affect receptor sites in a complementary 
fashion and have additive, or even super- 
additive effects. Ideally this is what we are 
looking for--an enhanced effect on combining 
two drugs, or even potentiation i  which we 
would get greater than twice the effect of each 
drug on its own. However, this is probably an 
optimistic target and a modest improvement, 
in effect, on combining two drugs would still be 
clinically important. 
Increasing knowledge about the way anti- 
epileptic drugs affects the glutamate, and ~- 
aminobutyric acid (GABA) neurotransmitters 
has led to the idea that these two mechanisms 
of action may be combined. For instance, viga- 
batrin works on GABA transaminase and in- 
creases GABA concentration. Tiagabine is 
another drug which also has a similar effect, as 
it inhibits the re-uptake of GABA into glial 
cells and neurones, thus increasing the concen- 
tration of GABA at the synapse. Lamotrigine, 
conversely, acts on the excitatory system on 
fast sodium channels, inhibiting the release 
of glutamate. Remacemide is thought o act 
as a non-competitive N-methyl-D-aspartate 
(NMDA) receptor antagonist, again reducing 
excitation. Felbamate probably acts partly on 
this glycine receptor and the belief is that it 
reduces excitation. 
The question we need to ask ourselves is: 
should we therefore combine felbamate with 
vigabatrin, or felbamate with tiagabine? Are 
there logical combinations which we can now 
develop? In published but uncontrolled work, 
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vigabatrin and lamotrigine have been claimed 
to be a good combination 6-s. These reports note 
a very good potentiating effect between these 
two drugs. Lamotrigine and valproate are also 
said to be a good combination--there is the 
pharmacokinetic mechanism but Pisani 9 and 
Panayiotopoulos I° claim there is a pharmaco- 
dynamic interaction as well, particularly in 
primary generalized seizures and idiopathic 
epilepsies. 
Controlled clinical trials need to be designed 
to evaluate these claims in a scientific way. 
Figure I shows a suggested model for aparallel 
,• Dummy A + Dummy ! ~ ,  Active A + Dummy Dummy A + Active 
ActiveA +Active B 
Fig. 1 : Testing drug combinations: parallel group design. 
group design to evaluate the effect of combi- 
nation therapy properly. Is Dummy A + 
Dummy B better or worse than either drug 
given alone? Is lamotrigine and vigabatrin 
combined better than either drug alone, from 
the outset? 
The second issue to be considered is the man- 
agement of patients who fail on either drug 
alone. Are they better off on the two drugs com- 
bined? These questions need proper evaluation 
in a scientific setting before this debate be- 
tween monotherapy and rational combination 
therapy can be solved. 
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